BCL2L1 and non-small cell lung carcinoma: Interestingly, in the cytoplasmic Bcl-xL high expression group, only 28.57% of NSCLC patients responded to radiotherapy, whereas the remaining 75.9% of patients experienced either recurrence or new metastasis (Fig. 3b).